Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
PDS Biotechnology Corporation
organization7 mentionslast seen Nov 10, 2026
A clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer.
Relationships 26
- PDS Biotechnology CorporationdevelopsPDS010199% confidence7 sources
- PDS Biotechnology CorporationdevelopsPDS030199% confidence7 sources
- PDS Biotechnology CorporationemploysFrank Bedu-Addo99% confidence6 sources
- PDS Biotechnology CorporationdevelopsVersamune cancer vaccine platform99% confidence2 sources
- PDS Biotechnology CorporationdevelopsPDS010399% confidence2 sources
- PDS Biotechnology CorporationdevelopsVersamune99% confidence2 sources
- Nant Capital, LLCinvests inPDS Biotechnology Corporation99% confidence1 source
- PDS Biotechnology CorporationemploysKirk Shepard98% confidence1 source
- Patrick Soon-Shionginvests inPDS Biotechnology Corporation97% confidence2 sources
- Nant Capital, LLCinvests inPDS Biotechnology Corporation96% confidence1 source
- PDS Biotechnology CorporationemploysBruce Wendel96% confidence1 source
- PDS Biotechnology CorporationemploysJohn A. Dawson96% confidence1 source
- PDS Biotechnology CorporationemploysDeborah A. Ramsdell96% confidence1 source
- PDS Biotechnology Corporationfunded byPIPE financing96% confidence1 source
- PDS Biotechnology CorporationdevelopsVersamune95% confidence1 source
- PDS Biotechnology CorporationemploysJames Banaag95% confidence1 source
- PDS Biotechnology CorporationemploysPatrick Soon-Shiong95% confidence1 source
- National Cancer Institutepartners withPDS Biotechnology Corporation94% confidence1 source
- PDS Biotechnology Corporationpartners withNational Cancer Institute92% confidence1 source
- Nant Capital, LLCinvests inPDS Biotechnology Corporation92% confidence1 source
- NantWorks, LLCinvests inPDS Biotechnology Corporation90% confidence1 source
- NantWorks, LLCpartners withPDS Biotechnology Corporation90% confidence1 source
- PDS Biotechnology CorporationauthoredVERSATILE-002 – A Phase 2 Study of PDS0101 HPV16-targeted T Cell Immunotherapy and Pembrolizumab Combination in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Nonrandomized Clinical Trial85% confidence1 source
- AB Group Ltd.invests inPDS Biotechnology Corporation85% confidence1 source
- PDS Biotechnology Corporationfunded bySeptember 2026 financing85% confidence1 source
- PDS Biotechnology CorporationauthoredVERSATILE-002 clinical trial75% confidence1 source
Relationship
Patrick Soon-Shionginvests inPDS Biotechnology Corporation
97% confidence2 supporting mentionsfrom Sep 1, 2026
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 20, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Dr. Patrick Soon-Shiong joined the Board of Directors, bringing prior experience obtaining FDA approval for an immunocytokine. A registrational Phase 3 protocol for PDS0301 in mCRC is in design. Following a September 2026 financing led by Nant Capital
- filingSEC EDGARSep 21, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Dr. Patrick Soon-Shiong joined the Board of Directors, bringing prior experience obtaining FDA approval for an immunocytokine